These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 1291337)

  • 1. [The mechanism of glucose intolerance in patients with Graves' disease].
    Kondo Y; Suzuki S; Gomi Y; Mayumi K; Sakamaki T; Inoue T; Iino S
    Nihon Naibunpi Gakkai Zasshi; 1992 Dec; 68(12):1257-68. PubMed ID: 1291337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperglucagonemia of insulin autoimmune syndrome induced by methimazole in a patient with Graves' disease.
    Yoshikawa H; Kawai K; Inoue S; Murayama Y; Fujieda K; Kuzuya N; Fujita T; Koide Y; Yamashita K
    Endocrinol Jpn; 1989 Feb; 36(1):125-34. PubMed ID: 2659308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin sensitivity and exogenous insulin clearance in Graves' disease. Measurement by the glucose clamp technique and continuous indirect calorimetry.
    Randin JP; Tappy L; Scazziga B; Jequier E; Felber JP
    Diabetes; 1986 Feb; 35(2):178-81. PubMed ID: 3510924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of plasma free thyroxine levels with insulin sensitivity and metabolic clearance rate of insulin in patients with hyperthyroid Graves' disease.
    Ohguni S; Notsu K; Kato Y
    Intern Med; 1995 May; 34(5):339-41. PubMed ID: 7647398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. beta-cell function and glucose and lipid oxidation in Graves' disease.
    Bech K; Damsbo P; Eldrup E; Beck-Nielsen H; Røder ME; Hartling SG; Vølund A; Madsbad S
    Clin Endocrinol (Oxf); 1996 Jan; 44(1):59-66. PubMed ID: 8706294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucose and insulin metabolism in patients with hyperthyroidism due to Graves' disease.
    Mano T; Kawakubo A; Yamamoto M
    Nagoya J Med Sci; 1994 Mar; 57(1-4):61-8. PubMed ID: 7898563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of arotinolol on insulin secretion and insulin clearance rate in patients with Graves' disease].
    Ohguni S; Notsu K; Tanaka J; Sato T; Kato Y
    Nihon Naibunpi Gakkai Zasshi; 1993 Aug; 69(7):650-8. PubMed ID: 7690718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin resistance in Graves' disease: a quantitative in-vivo evaluation.
    Cavallo-Perin P; Bruno A; Boine L; Cassader M; Lenti G; Pagano G
    Eur J Clin Invest; 1988 Dec; 18(6):607-13. PubMed ID: 3147186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin secretion and sensitivity in hyperthyroidism.
    Jap TS; Ho LT; Won JG
    Horm Metab Res; 1989 May; 21(5):261-6. PubMed ID: 2673961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methylprednisolone increases plasma leptin levels in Graves' hyperthyroidism patients with active Graves' ophthalmopathy.
    Song YM; Lee WJ; Chen MD; Kao CH; Sheu WH
    Horm Metab Res; 2000 Jul; 32(7):277-82. PubMed ID: 10965934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study of glucose and lipid metabolism by continuous indirect calorimetry in Graves' disease: effect of an oral glucose load.
    Randin JP; Scazziga B; Jéquier E; Felber JP
    J Clin Endocrinol Metab; 1985 Dec; 61(6):1165-71. PubMed ID: 3840492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin binding to monocytes and in vivo peripheral insulin sensitivity are normal in Graves' disease.
    Cavallo-Perin P; Bruno A; Bozzo C; Boine L; Estivi P; Martina V; Gallone G; Pagano G
    J Endocrinol Invest; 1988 Dec; 11(11):795-800. PubMed ID: 3066814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperglucagonemia and insulin-mediated glucose metabolism.
    Del Prato S; Castellino P; Simonson DC; DeFronzo RA
    J Clin Invest; 1987 Feb; 79(2):547-56. PubMed ID: 3543054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of hepatic insulin action in obese type 2 diabetic patients.
    Staehr P; Hother-Nielsen O; Levin K; Holst JJ; Beck-Nielsen H
    Diabetes; 2001 Jun; 50(6):1363-70. PubMed ID: 11375337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evaluation of insulin secretion and insulin resistance by hyperglycemic clamp in Graves disease patients with impaired glucose tolerance].
    Liang Z; Luo GC; Hu QH; Li MZ; Chen N; Yan DW; Chai J; Chen ZL; Li HY; Ou HT
    Zhonghua Nei Ke Za Zhi; 2007 Jul; 46(7):559-61. PubMed ID: 17959079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correction of insulin resistance in methimazole-treated patients with Graves disease.
    Tene C; Zárate A; Basurto L; Islas S; Revilla C; Ochoa R; Galván R; Santos P
    Rev Invest Clin; 2001; 53(6):531-5. PubMed ID: 11921526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Propranolol effect on plasma glucose, free fatty acid, insulin, and growth hormone in Graves' disease.
    Ortigosa JL; Mendoza F; Argote RM; Garcia G; Cervantes C; Parra A
    Metabolism; 1976 Nov; 25(11):1201-7. PubMed ID: 989880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of uremia and hemodialysis on the turnover and metabolic effects of glucagon.
    Sherwin RS; Bastl C; Finkelstein FO; Fisher M; Black H; Hendler R; Felig P
    J Clin Invest; 1976 Mar; 57(3):722-31. PubMed ID: 1249205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperthyroid Graves' disease causes insulin antagonism.
    Shen DC; Davidson MB
    J Clin Endocrinol Metab; 1985 May; 60(5):1038-41. PubMed ID: 3884646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Insulin resistance in patients with Graves' disease and reduced glucose tolerance. The normalization of fasting insulin secretion in parallel with the restoration of thyroid function].
    Custro N; Scafidi V; Costanza G; Corsello FP
    Minerva Med; 1990; 81(7-8):523-7. PubMed ID: 2199851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.